Fri, Oct 24, 2014, 9:45 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

Bio_guyo 28 posts  |  Last Activity: Oct 5, 2014 11:54 AM Member since: Dec 16, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bio_guyo bio_guyo Oct 5, 2014 11:54 AM Flag

    LOL 'blockbuster status' from FDA. You refer to breakthrough therapy designation - blockbusters and megablockbusters, the latter of which GILD has two and soon to be a third, are adjectives to describe product sales.

    I can't see GILD having any interest in ACHN.

  • bio_guyo bio_guyo Oct 3, 2014 7:47 AM Flag

    Of course the FDA approval of the single pill is already baked into GILD share price. Approval is a 99% certainty.

    What isn't fully realized, I believe, is the massive market for this drug. With the chance to be cured of HepC with a ribavarin- and interferon-free regimen, take a single pill once a day, and do so for as little as 8 weeks, patients will be breaking down their physician's doors to get prescribed the combo pill.

    Couple the increase in demand even over the mega-blockbuster Sovaldi with approval in Japan and a ramping up of sales in the major European markets, and the combo pill can be expected to top the record set by Sovaldi for most successful product launch in Pharm/Biotech history.

  • bio_guyo bio_guyo Sep 30, 2014 10:43 AM Flag

    One price cut is already upcoming in October. When the sovaldi/ledipasvir once-a-day pill is FDA approved, it will be priced at a small premium to sovaldi, but given the requirement of only 8 weeks of use for most patients and obviation of the need to add ribavirin, the treatment will cost less per patient than the current sovaldi regimen does now.

    The noise being made by the insurers is a joke.

  • Reply to

    My two cents

    by paintball_is_stellar Sep 27, 2014 7:25 PM
    bio_guyo bio_guyo Sep 27, 2014 8:12 PM Flag

    The most important presentation for affecting share price in the short-term was the NSCLC oral presentation.

    "The data show that patients in the predefined adenocarcinoma subgroup treated with the vintafolide plus docetaxel combination had a 27 percent reduction in risk of the disease worsening or death (HR=0.73, p=0.0899, one-sided test), and a 30 percent reduction in the risk of death (HR=0.70, p=0.1018) compared to docetaxel monotherapy. Stratified analysis, which adjusts for pre-defined patient characteristics in the trial, reflect a 49 percent reduction in the risk of death in patients with adenocarcinoma (HR=0.51, p=0.0147). These data include approximately 78 percent of the targeted number of events in the overall survival analysis."

  • Reply to

    Ok, it is 10:07....no news....disappointing.

    by wiz3dfx Sep 27, 2014 10:08 AM
    bio_guyo bio_guyo Sep 27, 2014 10:29 AM Flag

    At first glance, the trial result looks pretty good (3-4). Vintafolide added to doxil improves OS in a subgroup of NSCLC patients after stratification and selection of the adenocarcinoma subtype. The effect is statistically significant and comes without any major safety concerns compared with doxil alone.

  • Reply to

    Ok, it is 10:07....no news....disappointing.

    by wiz3dfx Sep 27, 2014 10:08 AM
    bio_guyo bio_guyo Sep 27, 2014 10:20 AM Flag

    - Interim Update of Overall Survival Analysis Shows 30 Percent Reduction of Risk of Death in Pre-Defined Adenocarcinoma Patient Subgroup -
    WEST LAFAYETTE, Ind., Sept. 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. ECYT, -1.61% today announced that the small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel extended overall survival (OS) for patients with folate receptor (FR) positive recurrent non-small cell lung cancer (NSCLC) compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress (ESMO), by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.

    The data show that patients in the predefined adenocarcinoma subgroup treated with the vintafolide plus docetaxel combination had a 27 percent reduction in risk of the disease worsening or death (HR=0.73, p=0.0899, one-sided test), and a 30 percent reduction in the risk of death (HR=0.70, p=0.1018) compared to docetaxel monotherapy. Stratified analysis, which adjusts for pre-defined patient characteristics in the trial, reflect a 49 percent reduction in the risk of death in patients with adenocarcinoma (HR=0.51, p=0.0147). These data include approximately 78 percent of the targeted number of events in the overall survival analysis. Overall survival in all patients, including those with squamous disease, reflect a 12 percent reduction in the risk of death (HR=0.88, p=0.2874) or 25 percent reduction when stratified (HR=0.75, p=0.1066). The primary endpoint of the study, as presented previously, showed that risk of disease worsening or death (progression-free survival, or PFS) was reduced by 25 percent for patients who received vintafolide plus docetaxel (HR=0.75, p=0.0696).

  • bio_guyo bio_guyo Sep 27, 2014 10:00 AM Flag

    You don't get a slot in a late-breaking oral presentation session with 'just safety'.

  • bio_guyo bio_guyo Sep 26, 2014 7:48 AM Flag

    Harvoni!

    Lol, it's a name we're going to be hearing a whole lot about over the next few years.

  • bio_guyo bio_guyo Sep 26, 2014 7:46 AM Flag

    An expected European approval, but still nice to get in an accelerated time frame. FDA approval should be coming within the next two weeks.

    I'm really looking forward to sovaldi/ledipasvir sales figures for November and December. I suspect there is something of a backlog of HepC patients waiting for the single pill approval so they could forego ribavarin.

  • Reply to

    ECYT Late breaking abstract

    by apfappa Sep 22, 2014 4:05 PM
    bio_guyo bio_guyo Sep 22, 2014 5:19 PM Flag

    "If abstract was good then we'd be flying"

    The abstract has old data on the effects of vintafolide + doxil on progression-free survival, but at the time it was written there were insufficient deaths in the vintafolide + doxil treatment arm to draw conclusions. Now, they have the OS data in hand. The fact that the abstract was moved to the prestigious late-breaking oral session raises the possibility that the combo produced a statistically significant prolongation of OS.

    We'll find out on the 27th.

  • Reply to

    control is living longer

    by dawginlife Sep 22, 2014 8:51 AM
    bio_guyo bio_guyo Sep 22, 2014 2:55 PM Flag

    I just had to quote this gem from earlier:

    "if control was 16, the trial would have likely been stopped for fertility"

    For futility, yes.

    I bought shares on today's dip.

  • Reply to

    Generics versus those who can pay.

    by portered115 Sep 15, 2014 10:37 AM
    bio_guyo bio_guyo Sep 21, 2014 7:13 AM Flag

    Anybody ever hear about medical insurance? It's what prevents someone in the US from needing to go to a poor country, where the price of a drug might be far less.

  • Reply to

    GILD raised FDA approval bar

    by xtandiinvestor Sep 19, 2014 2:27 PM
    bio_guyo bio_guyo Sep 20, 2014 6:00 PM Flag

    'No need to guess which one they will cover'

    Insurance will cover both Ledivaldi and the ABBV multi-pill treatment, so your post is garbage.

    Ledivaldi will be the dominant HepC treatment owing to its ease of use (which promotes patient compliance and, hence, real-world cure rates), benign side-effect profile, 8 week curative course for most patients, efficacy for those co-infected with HIV, and extraordinarily high cure rate.

  • Reply to

    Selling off as price is TOO high

    by shostakovich_quartet Sep 19, 2014 9:50 AM
    bio_guyo bio_guyo Sep 19, 2014 12:17 PM Flag

    Flip and not hold, that's your advise? Funny to the longs who bought GILD shares at 50, 65, and up to 90 over the past 18 months. Their held positions have quite a bit more profit accumulated in them than any short-term trade for at best a couple of points a share.

    Plus, since you've been advocating shorting the stock since 15 points ago, your stance doesn't have much credibility.

  • Reply to

    Article = Nonsense

    by pupertz Sep 18, 2014 1:01 AM
    bio_guyo bio_guyo Sep 18, 2014 7:00 AM Flag

    The low dropout rate on Sovaldi will be rendered irrelevant by Ledivaldi within a month. The latter doesn't need to be paired with ribavarin or IFN for most HepC patients, is a once-a-day pill, and in most cases will require only 8 and not 12 weeks of dosing.

    The ABBV multi-pill, twice-a-day regimen, on the other hand, will be more prone to causing dropouts before completion of a course of treatment.

  • Reply to

    Any more bad news..

    by filipinas4me Sep 17, 2014 11:34 AM
    bio_guyo bio_guyo Sep 17, 2014 11:43 AM Flag

    Since you consider the pancreatic cancer trial failure as material bad news for GILD, please enlighten us with how much you estimated that success in this indication was going to add to the bottom line.

    The ongoing trials of this drug in NASH are far more impactful to the GILD revenue projections than any of its potential oncology indications.

  • bio_guyo bio_guyo Sep 16, 2014 11:10 AM Flag

    You missed the 75% stock price appreciation over the past 18 months, and the reaching of all-time highs on nearly a daily basis over the past month.

  • Reply to

    No squealing Oink!! Oink!! today.

    by leemike957 Sep 12, 2014 1:34 PM
    bio_guyo bio_guyo Sep 12, 2014 1:41 PM Flag

    The stock is up over 50% since you started with the homophobic ranting.

    Are you going to be a sore ex-employee permanently?

  • bio_guyo bio_guyo Sep 12, 2014 11:59 AM Flag

    Source for your claim that it will be half the price of Sovaldi?

    At such a price, they would have to outpace Sovaldi sales to garner a decent share of the HepC market revenue. It isn't in their best interest to discount.

  • bio_guyo bio_guyo Sep 10, 2014 2:07 PM Flag

    A contract to provide Imbruvica to patients of the VA does not specify how many patients will require treatment. The 'size' of the contract is the maximum amount the VA is committed to spending to provide the drug to veterans in need.

VRTX
109.91+1.82(+1.68%)Oct 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.